SPRINT ¿¬±¸°¡ °íÇ÷¾Ð °¡À̵å¶óÀο¡ ¹ÌÄ¡´Â ¿µÇâ
The Impact of the SPRINT Trial on Hypertension Guidelines
´ëÇѳ»°úÇÐȸÁö 2016³â 91±Ç 1È£ p.12 ~ p.17
ÃÖÈ«»ó(Choi Hong Sang) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è¼ö¿Ï(Kim Soo-Wan) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
The most recent revision of the blood pressure guidelines adopted less aggressive blood pressure targets, particularly in patients with diabetes and chronic kidney disease, and the elderly. However, the Systolic Blood Pressure Intervention Trial (SPRINT) reported that lowering the systolic blood pressure to <120 mmHg resulted in a decreased risk of cardiovascular disease, compared with lowering the SBP to <140 mmHg, in adults with hypertension but without diabetes. This will likely lead to many changes in clinical practice. Such lowering of systolic blood pressure would benefit some categories of hypertensive patients at an increased risk of cardiovascular disease.
Å°¿öµå
Hypertension, SPRINT, Blood pressure
KMID :
0882420160910010012
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
The Systolic Blood Pressure Intervention Trial (SPRINT) reported that lowering the systolic blood pressure to <120 mmHg resulted in a decreased risk of cardiovascular disease, compared with lowering the SBP to <140 mmHg, in adults with hypertension but without diabetes.